Clinical Distribution and Drug Resistance of Acinetobacter baumannii in a Hospital from 2019 to 2021

Abstract

Objective: To analyze the clinical distribution and drug resistance of Acinetobacter baumannii (AB) and provide reference for the treatment of AB infection. Methods: AB isolated from clinical specimens of Huaihua First People’s Hospital from 2019 to 2021 were collected and identified by VITEK 2 Compact, an automated microbial identification and susceptibility testing system, in which drug sensitivity test was also performed. Excel was used for statistical analysis. Results: Among the 1,311 AB strains, 81.16% (1,064 strains) were from sputum samples, and the departments with the highest detections rates of AB were neurosurgery (24.33%), intensive care (15.48%) and infectious disease (11.44%). The drug sensitivity test showed that the resistance rate of 1,311 AB strains to compound sulfamethoxazole and amikacin was 28.38% and 20.54%, respectively, and the resistance rate to 10 other kinds of common antibiotics was more than 40%. Conclusion: The 1,311 AB strains isolated were widely distributed in clinical settings and had strong resistance to commonly used antibiotics. Therefore, it is necessary to strengthen the monitoring of pathogens and drug resistance, formulate reasonable and effective infection control measures, and ensure that antibiotics are used in a reasonable manner.